Almirall To Position Oral DMF For Psoriasis Ahead Of EU Biologics Use
Almirall aims to start selling its unpatented fumaric acid derivative throughout Europe in the third quarter for treating plaque psoriasis, but will not seek approval for the medicine in the US.
You may also be interested in...
Peter Guenter has steadied the ship at Almirall, and after seven months in the role he outlines his vision for the company in his first exclusive interview as CEO of Spain's largest pharma company.
The Spanish company has a lot riding on tildrakizumab, the psoriasis drug licensed from Sun Pharma which could get the green light in Europe before year-end. Until then, Almirall is scouring the market for bolt-on deals.
Changes in business processes in the US, and the launch of new products including a competitively priced Skilarence in the EU, are expected to help Almirall recover from setbacks over the coming months.